October 2nd 2024
Dual HER2 blockade with trastuzumab plus pertuzumab may serve as an effective option for hormone receptor–positive, HER2-positive metastatic breast cancer.
October 1st 2024
Cilta-cel reduced the risk of death by 45% compared with standard of care in patients with multiple myeloma, according to the CARTITUDE-4 study.
September 18th 2024
Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.
September 15th 2024
Encorafenib, cetuximab, and FOLFIRI demonstrate promising antitumor activity in patients with BRAF V600E-mutant metastatic colorectal cancer.
September 14th 2024
First-line combinations with trastuzumab deruxtecan showed initial efficacy in HER2-positive esophageal, gastric, and gastroesophageal junction cancers.
September 9th 2024
Neoadjuvant pembrolizumab plus chemotherapy led to greater pathologic regression vs placebo plus chemotherapy in early-stage non–small cell lung cancer.
September 5th 2024
Reid W. Merryman, MD, discusses notable advancements with minimal residual disease assays in lymphoma.
June 14th 2024
Ponatinib, chemo, and alloHSCT offer long-term survival in adult Ph+ ALL, per 4-year PONALFIL trial data at 2024 EHA Congress.
June 6th 2024
Cretostimogene grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC according to the phase 2 CORE-001 trial.
June 5th 2024
Treatment cessation of enzalutamide-containing regimens in responding patients had no impact on QOL in biochemically recurrent nmHSPC.
June 2nd 2024
Cabazitaxel plus abiraterone acetate and prednisone improved PSA response and extended PFS vs abiraterone acetate and prednisone in patients with mCRPC.
May 5th 2024
Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003.
May 4th 2024
18F-DCFPyL PSMA-PET imaging plus multi-parametric MRI improved the detection of clinically significant prostate cancer in low- and high-risk men on active surveillance.
January 26th 2024
Assessment of urinary MRD status identified and enabled quantification of molecular responses with nadofaragene firadenovec in BCG-unresponsive NMIBC.
October 22nd 2023
Frontline treatment with the combination of enfortumab vedotin-ejfv and pembrolizumab led to a statistically significant improvement in overall survival vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.
June 5th 2023
Lenvatinib plus pembrolizumab (Keytruda) showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma.
June 3rd 2023
Belzutifan plus lenvatinib generated responses and displayed a manageable safety profile in patients with advanced clear cell renal cell carcinoma whose disease progressed following treatment with a PD-1/L1 inhibitor and a VEGF TKI.
May 2nd 2023
Apalutamide plus androgen deprivation therapy with or without abiraterone acetate and prednisone improved prostate-specific antigen progression-free survival in patients with biochemically relapsed prostate cancer, according to long-term follow-up data from the phase 3 PRESTO trial.
April 29th 2023
A subgroup analysis of the phase 3 ARASENS trial showed that darolutamide plus androgen deprivation therapy elicited an overall survival benefit in North American patients with metastatic hormone-sensitive prostate cancer.
April 28th 2023
The use of zoledronic acid or other bisphosphonates was associated with a significant reduction in risk of fracture in patients with metastatic hormone-sensitive prostate cancer.